Biogen Inc  

(Public, NASDAQ:BIIB)   Watch this stock  
Find more results for BIIB
288.94
-1.19 (-0.41%)
Feb 17 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 287.76 - 291.90
52 week 223.02 - 333.65
Open 290.00
Vol / Avg. 2.02M/1.81M
Mkt cap 62.14B
P/E 17.09
Div/yield     -
EPS 16.91
Shares 215.95M
Beta 0.71
Inst. own 89%
Jan 26, 2017
Q4 2016 Biogen Inc Earnings Release
Jan 26, 2017
Q4 2016 Biogen Inc Earnings Call
Jan 9, 2017
Biogen Inc at JPMorgan Healthcare Conference - Q&A
Jan 9, 2017
Biogen Inc at JPMorgan Healthcare Conference
Jan 6, 2017
Biogen Inc Bioverativ Investor Day
Jan 5, 2017
Biogen Inc at Goldman Sachs CEOs Unplugged Conference
Jan 5, 2017
Bioverativ at Goldman Sachs CEOs Unplugged Conference
Dec 20, 2016
Biogen Inc Conference Call on CEO Transition - Webcast
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '16) 2016
Net profit margin 22.56% 32.28%
Operating margin 30.86% 44.99%
EBITD margin - 55.45%
Return on average assets 11.55% 17.44%
Return on average equity 21.47% 34.42%
Employees 7,400 -
CDP Score - 96 C

Address

225 Binney St
CAMBRIDGE, MA 02142-1031
United States - Map
+1-781-4642000 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Transcripts - SeekingAlpha
About Company - Wikipedia

Description

Biogen Inc., formerly Biogen Idec Inc., is a biopharmaceutical company. The Company operates in discovering, developing, manufacturing and delivering therapies to patients for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders segment. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for multiple sclerosis (MS), ELOCTATE for hemophilia A and ALPROLIX for hemophilia B, and FUMADERM for the treatment of severe plaque psoriasis. It also has a collaboration agreement with Genentech, Inc., a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL and follicular lymphoma, and other potential anti-CD20 therapies. It also develops late stage product candidates, including Aducanumab (BIIB037) for the treatment of Neurodegeneration, and Nusinersen for other programs.

Officers and directors

Stelios B. Papadopoulos Ph.D. Independent Chairman of the Board
Age: 67
Bio & Compensation  - Reuters
Michel Vounatsos Chief Executive Officer, Director
Age: 55
Bio & Compensation  - Reuters
Paul J. Clancy Chief Financial Officer, Executive Vice President - Finance
Age: 54
Bio & Compensation  - Reuters
Kenneth A. Di Pietro Executive Vice President - Human Resources
Age: 57
Bio & Compensation  - Reuters
Susan H. Alexander Esq. Executive Vice President, Chief Legal Officer and Corporate Secretary
Age: 60
Bio & Compensation  - Reuters
Michael D Ehlers M.D., Ph.D. Executive Vice President of Research and Development
Bio & Compensation  - Reuters
Steven H. Holtzman Executive Vice President - Corporate Development
Age: 63
Bio & Compensation  - Reuters
Adriana Karaboutis Executive Vice President - Technology , Business Solutions and Corporate Affairs
Age: 53
Bio & Compensation  - Reuters
Adam M. Koppel M.D. Ph.D. Executive Vice President - Strategy and Business Development
Age: 46
Bio & Compensation  - Reuters
Paul McKenzie Ph.D. Executive Vice President - Pharmaceutical Operations & Technology
Bio & Compensation  - Reuters